Clinical trial · Interventional
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objective: * To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4). * To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses. Secondary Objectives: * To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1 * To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2 * To determine antitumor activity in Segment 2
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| metoprolol | Drug | — | UNRESOLVED |
| midazolam | Drug | — | UNRESOLVED |
| omeprazol | Drug | — | UNRESOLVED |
| SAR302503 | Drug | Fedratinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Segment 1
- description
- two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
- interventionNames
- Drug: SAR302503
- Drug: omeprazol
- Drug: metoprolol
- Drug: midazolam
- type
- EXPERIMENTAL
- label
- Segment 2
- description
- SAR302503 500 mg once daily without food in 28-day per cycle
- interventionNames
- Drug: SAR302503
Primary outcomes (1)
- measure
- Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : * Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist * Signed informed consent Exclusion criteria: * Less than 18 years of age. * Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale) * Inability to follow study requirements and schedule * Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy * Serious medical illness at same time of study and/or significantly abnormal lab reports * Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding. * Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug * Continued toxic effects of prior chemotherapy * Evidence of other concurrent active malignancy * Other concurrent serious illness or medical condition * Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker. * Patients with Insulin-Dependent Diabetes Mellitus. * Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis \[NASH\]). * Inadequate organ function * History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
References
Publications (0)
Data not yet available